EP1353897A1 - Verfahren zur herstellung von monoamiden der dtpa - Google Patents
Verfahren zur herstellung von monoamiden der dtpaInfo
- Publication number
- EP1353897A1 EP1353897A1 EP02710013A EP02710013A EP1353897A1 EP 1353897 A1 EP1353897 A1 EP 1353897A1 EP 02710013 A EP02710013 A EP 02710013A EP 02710013 A EP02710013 A EP 02710013A EP 1353897 A1 EP1353897 A1 EP 1353897A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mixture
- mmol
- stirred
- dtpa
- precipitate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000004519 manufacturing process Methods 0.000 title abstract description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 97
- 239000002904 solvent Substances 0.000 claims abstract description 40
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract description 30
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 claims abstract description 20
- 150000004985 diamines Chemical class 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 155
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 60
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 46
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 36
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 30
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 21
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 15
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 claims description 3
- 239000012456 homogeneous solution Substances 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- KMQZCPJGOQEPBR-UHFFFAOYSA-N 1-hydroxy-4-phenyltriazole Chemical compound N1=NN(O)C=C1C1=CC=CC=C1 KMQZCPJGOQEPBR-UHFFFAOYSA-N 0.000 claims description 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 claims description 2
- SEULWJSKCVACTH-UHFFFAOYSA-N 1-phenylimidazole Chemical compound C1=NC=CN1C1=CC=CC=C1 SEULWJSKCVACTH-UHFFFAOYSA-N 0.000 claims description 2
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- IOEDDFFKYCBADJ-UHFFFAOYSA-M lithium;4-methylbenzenesulfonate Chemical compound [Li+].CC1=CC=C(S([O-])(=O)=O)C=C1 IOEDDFFKYCBADJ-UHFFFAOYSA-M 0.000 claims description 2
- OWNSEPXOQWKTKG-UHFFFAOYSA-M lithium;methanesulfonate Chemical compound [Li+].CS([O-])(=O)=O OWNSEPXOQWKTKG-UHFFFAOYSA-M 0.000 claims description 2
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 claims 1
- YMBWNYKEVPQWII-UHFFFAOYSA-N [Br].N1C=NC=C1 Chemical compound [Br].N1C=NC=C1 YMBWNYKEVPQWII-UHFFFAOYSA-N 0.000 claims 1
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 4
- WYMDDFRYORANCC-UHFFFAOYSA-N 2-[[3-[bis(carboxymethyl)amino]-2-hydroxypropyl]-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)CN(CC(O)=O)CC(O)=O WYMDDFRYORANCC-UHFFFAOYSA-N 0.000 abstract 1
- GTDPSWPPOUPBNX-UHFFFAOYSA-N ac1mqpva Chemical compound CC12C(=O)OC(=O)C1(C)C1(C)C2(C)C(=O)OC1=O GTDPSWPPOUPBNX-UHFFFAOYSA-N 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 156
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 84
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- 238000004128 high performance liquid chromatography Methods 0.000 description 50
- 239000002244 precipitate Substances 0.000 description 49
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 42
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 42
- 235000019253 formic acid Nutrition 0.000 description 42
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 38
- 239000012043 crude product Substances 0.000 description 26
- 238000010438 heat treatment Methods 0.000 description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- 239000007787 solid Substances 0.000 description 24
- 239000007983 Tris buffer Substances 0.000 description 23
- 238000000921 elemental analysis Methods 0.000 description 23
- 239000000126 substance Substances 0.000 description 23
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 22
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 238000000746 purification Methods 0.000 description 19
- 150000001412 amines Chemical class 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 12
- 150000001408 amides Chemical class 0.000 description 10
- -1 10-carboxydecylcarbamoylmethyl Chemical group 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 150000008064 anhydrides Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- FTQWRYSLUYAIRQ-UHFFFAOYSA-N n-[(octadecanoylamino)methyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCNC(=O)CCCCCCCCCCCCCCCCC FTQWRYSLUYAIRQ-UHFFFAOYSA-N 0.000 description 3
- 238000007127 saponification reaction Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- WGENWPANMZLPIH-UHFFFAOYSA-N 4-decylaniline Chemical compound CCCCCCCCCCC1=CC=C(N)C=C1 WGENWPANMZLPIH-UHFFFAOYSA-N 0.000 description 2
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical compound C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 239000005700 Putrescine Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000010640 amide synthesis reaction Methods 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- JYHBPKNOVQWAPT-UHFFFAOYSA-N chloroform;formic acid Chemical compound OC=O.ClC(Cl)Cl JYHBPKNOVQWAPT-UHFFFAOYSA-N 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 150000001470 diamides Chemical class 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- GUOSQNAUYHMCRU-UHFFFAOYSA-N 11-Aminoundecanoic acid Chemical compound NCCCCCCCCCCC(O)=O GUOSQNAUYHMCRU-UHFFFAOYSA-N 0.000 description 1
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 1
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
- DJHGAFSJWGLOIV-UHFFFAOYSA-N Arsenic acid Chemical compound O[As](O)(O)=O DJHGAFSJWGLOIV-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- ISKQADXMHQSTHK-UHFFFAOYSA-N [4-(aminomethyl)phenyl]methanamine Chemical compound NCC1=CC=C(CN)C=C1 ISKQADXMHQSTHK-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- SZTOOPQPYOUHEY-UHFFFAOYSA-N aminomethyl propanoate Chemical compound CCC(=O)OCN SZTOOPQPYOUHEY-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- LHNICELDCMPPDE-UHFFFAOYSA-N anthracen-9-amine Chemical compound C1=CC=C2C(N)=C(C=CC=C3)C3=CC2=C1 LHNICELDCMPPDE-UHFFFAOYSA-N 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 150000008430 aromatic amides Chemical class 0.000 description 1
- 229940000488 arsenic acid Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000008280 blood Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- QHNDMDXXMVBFTM-UHFFFAOYSA-N ethyl 11-aminoundecanoate Chemical compound CCOC(=O)CCCCCCCCCCN QHNDMDXXMVBFTM-UHFFFAOYSA-N 0.000 description 1
- WASRJUXSLHUONH-UHFFFAOYSA-N ethyl 4-aminocyclohexane-1-carboxylate Chemical compound CCOC(=O)C1CCC(N)CC1 WASRJUXSLHUONH-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- YSSCXCGSGIFDGS-UHFFFAOYSA-N n,2,2,4-tetramethyl-1,3-dioxolan-4-amine Chemical compound CNC1(C)COC(C)(C)O1 YSSCXCGSGIFDGS-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000006894 reductive elimination reaction Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- SJMDMGHPMLKLHQ-UHFFFAOYSA-N tert-butyl 2-aminoacetate Chemical compound CC(C)(C)OC(=O)CN SJMDMGHPMLKLHQ-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
Definitions
- the present invention describes a new process for the preparation of dieylenetriarninepentaacetic acid monoamides (DTPA monoamides).
- DTPA monoamides dieylenetriarninepentaacetic acid monoamides
- Monoamides of DTPA have been extensively described in the literature. They serve as complexing agents for metal complexes that have been used in imaging diagnostics.
- the compound 3,6-bis (carboxymethyl) -9- (10-carboxydecylcarbamoylmethyl) -3,6,9-triazaundecansä ⁇ re "mono-Puchel" is described as a potential liver contrast agent.
- Further monoamides from DTPA for illustration of organs can be found in WO 95/27705, EP 529 175, WO 95/33494.
- Aromatic amides for liver diagnosis have been described by Green Cross in EP 603 403, US 5,453,264 and US 5,575,986 Classes of compounds, such as, for example, blood pool contrast media (polylysine-DTPA, EP 331 616, dendrimers EP 430 863), which contain monoamides of DTPA: Different methods for the production of monoamides (starting from DTPA), as described in US 5,021,571 or in EP 263 059, formula scheme 1:
- the monoamides obtained in this way are obtained in a total of 6 stages.
- the overall yield is relatively low, since the partial saponification of the ester groups and the subsequent chromatography greatly reduce the yield on the intermediate (4).
- the subsequent ester hydrolysis and acidic work-up provides the desired monoamides with free carboxylic acids.
- a disadvantage of both of the processes described above is that the subsequent saponification step saponifies ester functions which may be present in the amine of the general formula RR 2 NH.
- the use of t-butyl ester or benzyl ester is also problematic since the residues R J and R 2 are attacked in the acidic or reductive cleavage.
- Krejcarek takes a different path. Krejcarek starts from DTPA, produces a pentaamonium salt and converts it with an equivalent of chloroformate to the mono-mixed anhydride of DTPA and then with an amine [Krejcarek and Tucker, Biochem. Biophys. Res. Commun. 77, 581 (1977), WO 91/05762].
- a disadvantage of this process is that it cannot be determined whether the amide formation takes place at one of the terminal or at the central acetic acid.
- Another disadvantage of this process is the high amount of by-product. 5 equivalents of amine salt must be disposed of, 4 of which were not involved in the activation of the carbonyl group.
- the monoamide formed in the first step apparently has a higher solubility and is therefore more reactive than the excess bisanhydride and preferentially reacts. This is observed in solvents such as DMF, DMSO, formamide. In case of Settlements ⁇ 50 ° C, e.g. room temperature, the formation of (11) is observed almost exclusively.
- the invention relates to a process for the preparation of monoamides of DTPA of the general formula (I)
- DMSO dimethyl sulfoxide
- DMF dimethylformamide
- n and A have the meaning given above, at temperatures of 10-70 ° C and a reaction time of 1-24 hours.
- the solubilizer is used in amounts of 1-10, preferably 2-5 equivalents based on the DTPA bisanhydride (2).
- the homogeneous solution of the DTPA bisanhydride (2) and the solubilizer in DMSO, DMF or their mixtures obtained by heating (up to 150 ° C) is allowed to cool to the desired reaction temperature and then with the amine II, optionally in a solvent such as e.g. DMSO, DMF, pyridine, dioxane, tetrahydrofuran or mixtures thereof dissolved.
- a reaction temperature of 15-50 ° C. and a reaction time of 3-8 hours are preferred.
- amines of natural or synthetic origin are used: primary, secondary, aliphatic, aromatic, araliphatic mono- and diamines, with the diamines still mixed primary / secondary or mixed aliphatic / aromatic / araliphatic diamines can occur.
- Amines of natural origin come from the classes steroids, alkaloids, peptides, amino acids, nucleotides, nucleosides, porphyrins and carbohydrates.
- auxiliary base can either be initially introduced or added together with the amine A (H) n . It is also possible to use the amines in the form of their salts. In this case, however, an excess of auxiliary base is required.
- solubilizers are used:
- lithium chloride lithium bromide, lithium iodide, lithium mesylate, lithium tosylate
- Hal chlorine, iodine, bromine
- Imidazole phenylimidazole, N-methyl-imidazole, 4-nitrophenol, pentafluorophene, N-hydroxysuccinimide, N-hydroxy-phenyl-triazole
- imidazole is used as a solubilizer.
- Organic bases such as pyridine, triethylamine, N-ethylmorpholine and imidazole are preferably used as the auxiliary base.
- DTPA bisanhydride can be converted in concentrations up to 30%. It has proven to be advantageous to also increase the amount of solubilizer at concentrations between 20-30%. For working up, a little water is added (1 equ.
- the desired product can be purified chromatographically by crystallization, by ion exchanger chromatography, by chromatography on silica gel or RP material. In some cases it has proven to be advantageous to dry the precipitate obtained above, to make an HPLC purity determination and to proceed to the next step with the crude product (for example when complexing with metals).
- a solvent such as diethyl ether, acetone, methyl t-butyl ether (MTB), diisopropyl ether, tetrahydrofuran (THF) or mixtures of these and precipitated and the precipitate filtered off.
- the desired product can be purified chromatographically by crystallization, by ion exchanger chromatography, by chromatography on silica gel or RP material. In some cases it has proven to be advantageous to dry the precipitate obtained above, to make an HPLC purity determination and to proceed to the next step with the crude product (for example when complexing with metals).
- HPLC of the crude product showed a monoamide: diamide ratio of 70:30. Yield: 24.0 g (51% of theory) of a colorless solid. Water content: 0.5%. HPLC purity:> 97%.
- 35J g (100 mmol) of DTPA bisanhydride are dissolved in 350 ml of dimethyl sulfoxide (with gentle heating) with the addition of 12.72 g (300 mmol) of lithium bromide.
- the mixture is allowed to cool to 40 ° C. and a mixture of 8.71 g (100 mmol) of morpholine and 20.24 g (200 mmol) of triethylamine within 30 minutes. Stir for 6 hours
- 35J g (100 mmol) of DTPA bisanhydride are dissolved in 350 ml of dimethyl sulfoxide (with gentle heating) with the addition of 12.72 g (300 mmol) of lithium chloride.
- the mixture is allowed to cool to 35 ° C. and a mixture of 23.3 g (100 mmol) of 4-decyl-aniline and 23.7 g (300 mmol) of pyridine (dissolved in 25 ml of dimethyl sulfoxide) is added dropwise over the course of 30 minutes.
- the mixture is stirred at 35 ° C. for 5 hours. It is cooled to room temperature, 1.8 g (100 mmol) of water are added and the mixture is stirred for 10 minutes.
- 35J g (100 mmol) of DTPA bisanhydride are dissolved with the addition of 12.72 g (300 mmol) of lithium chloride in 350 ml of dimethyl sulfoxide (with gentle heating).
- the mixture is allowed to cool to 30 ° C. and a mixture of 12.3 g (100 mmol) of 4-methoxy-aniline and 30.4 g (300 mmol) of triethylamine (dissolved in 20 ml of dimethyl sulfoxide) is added dropwise over the course of 30 minutes.
- the mixture is stirred at 30 ° C. for 4 hours. It is cooled to room temperature, 1.8 g (100 mmol) of water are added and the mixture is stirred for 10 minutes.
- HPLC of the crude product showed a ratio of monoamide: other amides of 50:50. Yield: 18.6 g (44% of theory based on the diamine used) of a colorless solid. Water content: 0.9%. HPLC purity:> 96%.
- 35J g (100 mmol) of DTPA bisanhydride are dissolved in 350 ml of dimethylformamide with the addition of 47.6 g (700 mmol) of imidazole (with gentle heating).
- the mixture is allowed to cool to 50 ° C. and 14.7 g (100 mmol) of 3-trifluoromethyl-aniline (dissolved in 20 ml of dimethylformamide) are added dropwise over the course of 30 minutes.
- the mixture is stirred at 50 ° C. for 4 hours. It is cooled to room temperature, 1.8 g (100 mmol) of water are added and the mixture is stirred for 10 minutes.
- HPLC of the crude product showed a ratio of monoamide: diamide of 71:29. Yield: 27.5 g (51% of theory) of a colorless solid. Water content: 0.6%. HPLC purity:> 97%.
- the HPLC of the crude product showed a ratio of bis (monoamide): diamides of 69:31.
- HPLC of the crude product showed a ratio of monoamide: diamide of 70:30. Yield: 23.2 g (50% of theory) of a colorless solid. Water content: 0.9%. HPLC purity:> 97%.
- 35J g (100 mmol) of DTPA bisanhydride are dissolved with the addition of 54.5 g (800 mmol) of imidazole in 350 ml of dimethylformamide (with gentle heating).
- the mixture is allowed to cool to 50 ° C. and a mixture of 10.72 g (100 mmol) of benzylamine and 20.24 g (200 mmol) of triethylamine (dissolved in 20 ml of dimethylformamide) is added dropwise over the course of 30 minutes.
- the mixture is stirred at 50 ° C. for 4 hours. It is cooled to room temperature, 1.8 g (100 mmol) of water are added and the mixture is stirred for 10 minutes.
- Lithium bromide dissolved in 350 ml of dimethyl sulfoxide (with gentle heating). The mixture is allowed to cool to 35 ° C. and a mixture of 19.33 g (100 mmol) of 9-aminoanthracene and 23J g (300 mmol) of pyridine (dissolved in 25 ml of dimethyl sulfoxide) is added dropwise within 30
- HPLC of the crude product showed a ratio of monoamide: diamide of 72:28. Yield: 26.3 g (49% of theory) of a colorless solid. Water content: 0.6%. HPLC purity:> 97%.
- HPLC of the crude product showed a ratio of monoamide: diamide of 72:28. Yield: 26.3 g (49% of theory) of a colorless solid. Water content: 0.6%. HPLC purity:> 97%.
- Process B conversion of amine / small excess of anhydride, without solubilizer in DMSO, (WO 96/00079)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10105014 | 2001-01-26 | ||
| DE2001105014 DE10105014C2 (de) | 2001-01-26 | 2001-01-26 | Neues Verfahren zur Herstellung von Monoamiden der DTPA |
| PCT/EP2002/000421 WO2002059076A1 (de) | 2001-01-26 | 2002-01-16 | Verfahren zur herstellung von monoamiden der dtpa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1353897A1 true EP1353897A1 (de) | 2003-10-22 |
Family
ID=7672820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02710013A Withdrawn EP1353897A1 (de) | 2001-01-26 | 2002-01-16 | Verfahren zur herstellung von monoamiden der dtpa |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1353897A1 (de) |
| JP (1) | JP2004525107A (de) |
| DE (1) | DE10105014C2 (de) |
| NO (1) | NO20033356L (de) |
| WO (1) | WO2002059076A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2488819A1 (en) * | 2002-03-28 | 2003-11-06 | Rutgers, The State University Of New Jersey | Bis-transition-metal-chelate-probes |
| TW200523341A (en) * | 2003-09-26 | 2005-07-16 | Basf Ag | Free radical scavengers as stabilizers of polymerizable compounds |
| EP1518916A1 (de) * | 2003-09-26 | 2005-03-30 | Basf Aktiengesellschaft | Radikalfänger als stabilisatoren polymerisationsfähiger Verbindungen |
| JP5004438B2 (ja) * | 2005-06-09 | 2012-08-22 | 行政院原子能委員会核能研究所 | Dtpa誘導体の製造方法 |
| SE533165C2 (sv) * | 2008-06-13 | 2010-07-13 | Chemseq Internat Ab | Kemikalie och förfarande för komplexbindning av metalljoner, som är minst tvåvärda |
| US10286090B2 (en) | 2014-12-11 | 2019-05-14 | Rf Therapeutics Inc. | Targeted contrast agents comprising a hydrazide functional group |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987002708A1 (en) * | 1985-10-24 | 1987-05-07 | Siska Diagnostics, Inc. | Lanthanide chelate-tagged nucleic acid probes |
| WO1994001393A1 (fr) * | 1992-07-03 | 1994-01-20 | The Green Cross Corporation | Nouveau chelateur, complexe compose dudit chelateur et d'un atome metallique, et agent diagnostique renfermant ledit complexe |
| USH1312H (en) * | 1992-05-28 | 1994-05-03 | Cytogen Corporation | Method for the preparation of gyk-dtpa |
| US5571498A (en) * | 1994-06-02 | 1996-11-05 | Hemagen/Pfc | Emulsions of paramagnetic contrast agents for magnetic resonance imaging (MRI). |
| DE19652386A1 (de) * | 1996-12-04 | 1998-06-10 | Schering Ag | Verfahren zur Herstellung von Metallkomplexcarbonsäureamiden |
-
2001
- 2001-01-26 DE DE2001105014 patent/DE10105014C2/de not_active Expired - Fee Related
-
2002
- 2002-01-16 JP JP2002559379A patent/JP2004525107A/ja not_active Withdrawn
- 2002-01-16 WO PCT/EP2002/000421 patent/WO2002059076A1/de not_active Ceased
- 2002-01-16 EP EP02710013A patent/EP1353897A1/de not_active Withdrawn
-
2003
- 2003-07-25 NO NO20033356A patent/NO20033356L/no not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| See references of WO02059076A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE10105014C2 (de) | 2003-03-27 |
| JP2004525107A (ja) | 2004-08-19 |
| NO20033356L (no) | 2003-09-24 |
| NO20033356D0 (no) | 2003-07-25 |
| WO2002059076A1 (de) | 2002-08-01 |
| DE10105014A1 (de) | 2002-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69117768T2 (de) | Neues verfahren zur darstellung von formoterol und vewandten verbindungen | |
| DE19508058A1 (de) | Verfahren zur Herstellung von DTPA-Tetraestern der terminalen Carbonsäuren und deren Verwendung zur Herstellung pharmazeutischer Mittel | |
| EP1353897A1 (de) | Verfahren zur herstellung von monoamiden der dtpa | |
| DE69010745T2 (de) | Verbindungen und Komplexe, besonders verwendbar für ärztliche Darstellung. | |
| DE2660626C2 (de) | 3-Amino-2-hydroxy-4-phenyl-butansäure-Derivate und Verfahren zu ihrer Herstellung | |
| DE69302544T2 (de) | 2-amino-1,2,3,4-tetrahydronaphthalen derivate mit wirkung auf das kardiovasculäre system, verfahren zu deren herstellung und deren pharmazeutische zusammensetzungen | |
| DE3217547C2 (de) | ||
| DE68912811T2 (de) | Amide von Cyclomethylen-1,2 bicarbonsäure mit therapeutischer Wirkung, Verfahren zu deren Herstellung sowie diese enthaltende pharmazeutische Zusammensetzungen. | |
| EP0094633B1 (de) | Spiro-2-aza-alkan-3-carbonitrile, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE887651C (de) | Verfahren zur Herstellung von Aminoketonen | |
| DE68911237T2 (de) | Nichtionische Trijodbenzin-Verbindungen und diese enthaltende Kontrastmittel. | |
| EP1607090B1 (de) | Asimadolin für die Behandlung des Irritable Bowel Syndroms | |
| EP0029909A1 (de) | Verfahren zur Herstellung von Säureamiden, Verwendung des Verfahrens und Morpholino-äthyl-isocyanid | |
| DE19524337C1 (de) | Verfahren zur Herstellung von beta-Amino-alpha-hydroxycarbonsäuren und deren Derivaten | |
| DE69210629T2 (de) | 5-aminosulfonanilid-verbindungen | |
| DE2623257C2 (de) | Verfahren zur Herstellung von N-Alkenyl-2-aminomethyl-pyrrolidinen | |
| DE69814771T2 (de) | Gamma-oxohomophenylalanin derivate und ein verfahren zur herstellung von homophenylalanin derivaten durch reduktion derselben | |
| DD283804A5 (de) | Verfahren zur herstellung von neuen nichtionischen, iodierten triiodbenzen-verbindungen | |
| EP1430018B1 (de) | Verfahren zur herstellung von beta-alaninamiden | |
| DE19816929A1 (de) | Neue substituierte Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen | |
| US6677483B2 (en) | Process for the production of monoamides of DTPA | |
| DE3217693C2 (de) | ||
| DE2541426A1 (de) | Neue heterocyclische verbindungen, ihre herstellung und ihre verwendung | |
| CH651820A5 (de) | Aminosaeurederivate, verfahren zu ihrer herstellung und ihre verwendung in pharmazeutika. | |
| DE1493965C (de) | Verfahren zum Herstellen von Racema ten optisch aktiver Nitrile |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20030605 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| 17Q | First examination report despatched |
Effective date: 20050425 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER SCHERING PHARMA AG |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20081217 |